Page last updated: 2024-12-07

hexamethonium chloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Hexamethonium chloride is a quaternary ammonium compound that acts as a ganglionic blocker, inhibiting the transmission of nerve impulses through autonomic ganglia. It was first synthesized in the 1940s and was initially studied for its potential therapeutic effects in treating hypertension and other cardiovascular conditions. However, its use has declined due to its significant side effects, such as hypotension, constipation, and urinary retention. Hexamethonium chloride is still used in research to study the function of autonomic ganglia and the mechanisms of neurotransmission. It is also used as a tool to investigate the role of autonomic nervous system in various physiological processes. '

Cross-References

ID SourceID
PubMed CID93550
CHEMBL ID105608
SCHEMBL ID22332
MeSH IDM0028072

Synonyms (61)

Synonym
hexamethylene(bistrimethylammonium)chloride
nsc 21643
alpha,omega-bis(trimethylammonium)hexane dichloride
ai3-61433
ammonium, hexamethylenebis(trimethyl-, dichloride
einecs 200-465-1
1,6-hexanediaminium, n,n,n,n',n',n'-hexamethyl-, dichloride
hexon chloride
60-25-3
hexamethonium chloride
hexamethonium dichloride
hexone chloride
esomid chloride
methium chloride
hexamethylenebis(trimethylammonium) chloride
chloor-hexaviet
hiohex chloride
bistrium chloride
nsc-21643
hexameton chloride
hexamethionium chloride
hestrium chloride
meton
EU-0100613
NCGC00093988-01
n,n,n,n',n',n'-hexamethyl-1,6-hexanediaminium dichloride
H 2138
CHEMBL105608
hexane-1,6-bis(trimethylammonium chloride)
hexamethylenebis(trimethylammonium chloride)
H0090
n,n,n,n',n',n'-hexamethyl-1,6-hexanediammonium dichloride
trimethyl-[6-(trimethylazaniumyl)hexyl]azanium
HMS3261L08
unii-tiv4q933fu
1,6-hexanediaminium, n1,n1,n1,n6,n6,n6-hexamethyl-, chloride (1:2)
tiv4q933fu ,
LP00613
hexamethonium chloride [mart.]
hexamethonium chloride [mi]
hexamethonium chloride [who-dd]
n,n,n,n',n',n'-hexamethylhexane-1,6-diaminium dichloride
CCG-221917
SCHEMBL22332
tox21_500613
NCGC00261298-01
tox21_303898
dtxcid1024700
NCGC00357009-01
dtxsid3044700 ,
cas-60-25-3
mfcd00031563
SR-01000075320-1
sr-01000075320
n1,n1,n1,n6,n6,n6-hexamethylhexane-1,6-diaminium chloride
hexone chloride; hiohex chloride; methium chloride; meton
hexamethonium (chloride)
Q27289985
trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;dichloride
trimethyl[6-(trimethylazaniumyl)hexyl]azanium dichloride
AS-81608
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency39.81070.003245.467312,589.2998AID1705
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency26.60320.001022.650876.6163AID1224838; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency17.80950.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency11.81200.000817.505159.3239AID1159527; AID1159531
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02240.035520.977089.1251AID504332
neuropeptide S receptor isoform AHomo sapiens (human)Potency19.95260.015812.3113615.5000AID1461
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID241212Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Defining determinant molecular properties for the blockade of the apamin-sensitive SKCa channel in guinea-pig hepatocytes: the influence of polarizability and molecular geometry.
AID192763Maximum rate of rise of the left ventricular isovolumetric pressure was measured after iv administration of 5 mg/kg in anesthetized rats1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID197302Changes in systolic blood pressure following iv administration at (12 umol/kg)anesthetized rats2001Journal of medicinal chemistry, Aug-30, Volume: 44, Issue:18
Novel hypotensive agents from Verbesina caracasana. 8. Synthesis and pharmacology of (3,4-dimethoxycinnamoyl)-N(1)-agmatine and synthetic analogues.
AID193764Change in heart rate after iv administration of 5 mg/kg in anesthetized rats1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID170663Tested for the change in diastolic blood pressure administered at 12 ug/kg intravenously in anesthetized rats1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Novel hypotensive agents from Verbesina caracasana. 2. Synthesis and pharmacology of caracasanamide.
AID171803Change in systolic blood pressure after iv administration of 12 uM/kg in anesthetized rats1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID192798Maximum rate of rise of the left ventricular isovolumetric pressure administered at 12 uM/kg iv in anesthetized rats1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Novel hypotensive agents from Verbesina caracasana. 2. Synthesis and pharmacology of caracasanamide.
AID146934Binding affinity nicotinic acetylcholine receptor alpha-7 was evaluated by its ability to inhibit [3H]methyllycaconitine ([3H]-MLA) binding to rat brain membranes2002Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21
bis-Azaaromatic quaternary ammonium analogues: ligands for alpha4beta2* and alpha7* subtypes of neuronal nicotinic receptors.
AID192745Maximum rate of rise of the left ventricular isovolumetric pressure was measured after iv administration of 12 uM/kg in anesthetized rats1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID400107Antihypertensive activity in anesthetized SHR rat assessed as decrease in heart rate at 20 mg/kg, iv after 1 to 1.5 mins1998Journal of natural products, Mar, Volume: 61, Issue:3
Cardiovascular effects of aspidofractinine-type alkaloids from Kopsia.
AID193699Percent change in systolic blood pressure (mmHg)in anesthetized rats by i.v. administration1999Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22
Further hypotensive metabolites from Verbesina caracasana.
AID171665Change in diastolic blood pressure after iv administration of 5 mg/kg in anesthetized rats1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID400108Antihypertensive activity in anesthetized SHR rat assessed as decrease in basal mean arterial blood pressure at 20 mg/kg, iv after 10 mins1998Journal of natural products, Mar, Volume: 61, Issue:3
Cardiovascular effects of aspidofractinine-type alkaloids from Kopsia.
AID170829Tested for the change in systolic blood pressure administered at 12 ug/kg intravenously in anesthetized rats1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Novel hypotensive agents from Verbesina caracasana. 2. Synthesis and pharmacology of caracasanamide.
AID171645Change in diastolic blood pressure after iv administration of 12 uM/kg in anesthetized rats1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID400109Antihypertensive activity in anesthetized SHR rat assessed as decrease in heart rate at 20 mg/kg, iv after 10 mins1998Journal of natural products, Mar, Volume: 61, Issue:3
Cardiovascular effects of aspidofractinine-type alkaloids from Kopsia.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID193688Percent change in heart rate expressed in beats / min in anesthetized rats by i.v. administration1999Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22
Further hypotensive metabolites from Verbesina caracasana.
AID197294Changes in diastolic blood pressure following iv administration at (12 umol/kg)anesthetized rats2001Journal of medicinal chemistry, Aug-30, Volume: 44, Issue:18
Novel hypotensive agents from Verbesina caracasana. 8. Synthesis and pharmacology of (3,4-dimethoxycinnamoyl)-N(1)-agmatine and synthetic analogues.
AID193763Change in heart rate after iv administration of 12 uM/kg in anesthetized rats1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID146468Binding affinity for nicotinic acetylcholine receptor alpha4-beta2 was evaluated by its ability to inhibit [3H]NIC binding to rat brain membranes2002Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21
bis-Azaaromatic quaternary ammonium analogues: ligands for alpha4beta2* and alpha7* subtypes of neuronal nicotinic receptors.
AID193680Maximum rate of rise of the left ventricular isovolumetric pressure (dP/dt, an index of cardiac inotropism in mmHg/sec)in anesthetized rats by i.v. administration1999Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22
Further hypotensive metabolites from Verbesina caracasana.
AID171823Change in systolic blood pressure after iv administration of 5 mg/kg in anesthetized rats1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID400106Antihypertensive activity in anesthetized SHR rat assessed as decrease in basal mean arterial blood pressure at 20 mg/kg, iv after 1 to 1.5 mins1998Journal of natural products, Mar, Volume: 61, Issue:3
Cardiovascular effects of aspidofractinine-type alkaloids from Kopsia.
AID180830Tested for change in heart rate administered at 12 uM/kg iv in anesthetized rats1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Novel hypotensive agents from Verbesina caracasana. 2. Synthesis and pharmacology of caracasanamide.
AID193687Percent change in diastolic blood pressure (mmHg)in anesthetized rats by i.v. administration1999Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22
Further hypotensive metabolites from Verbesina caracasana.
AID301621Inhibition of C57BL/6 mouse synaptosomal choline transporter2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Inhibition of choline transport by redox-active cholinomimetic bis-catechol reagents.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (36.36)18.2507
2000's5 (45.45)29.6817
2010's1 (9.09)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.43 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]